New Posts New Posts RSS Feed - New Immunotherapy Trial for Advanced TNBC
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

New Immunotherapy Trial for Advanced TNBC

 Post Reply Post Reply
Author
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 13317
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Topic: New Immunotherapy Trial for Advanced TNBC
    Posted: Jun 29 2020 at 4:28pm
UbiVac Announces Clinical Trial Collaboration with Bristol Myers Squibb on Combination Immunotherapy for Advanced Triple Negative Breast Cancer
Phase Ib study to combine UbiVac’s DRibble® Platform Vaccine, DPV-001 with anti-OX40 (BMS-986178) and Opdivo (nivolumab) to test hypothesis that this combination will augment anticancer immunity in advanced triple negative breast cancer
 

PORTLAND, Ore.--(BUSINESS WIRE)--UbiVac, Inc. (www.ubivac.com) today announced it has entered into a clinical trial collaboration with Bristol Myers Squibb Company(NYSE:BMY) to evaluate the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product, DPV-001™, a first-in-class cancer vaccine that exploits autophagy, in combination with Bristol Myers Squibb’s anti-OX40 (BMS-986178) combined with sequenced administration of the programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab). The Phase 1b multicenter trial will test the hypothesis that combination immunotherapy with the DPV-001 cancer vaccine and anti-OX40 will augment anticancer immunity in patients with advanced triple negative breast cancer. . . .

This is the first clinical trial to combine a cancer vaccine (DPV-001), that educates the immune system to destroy cancer cells, with a T cell agonist, Bristol Myers Squibb’s anti-OX40 (BMS-986178), that amplifies immune system activity. Patients also will receive anti-programmed death 1 immune checkpoint therapy, Bristol Myers Squibb’s Opdivo, which takes the brakes off the immune system.

https://www.biospace.com/article/releases/ubivac-announces-clinical-trial-collaboration-with-bristol-myers-squibb-on-combination-immunotherapy-for-advanced-triple-negative-breast-cancer/?s=86



DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
jheffron View Drop Down
Newbie
Newbie
Avatar

Joined: Mar 09 2020
Status: Offline
Points: 7
Post Options Post Options   Thanks (0) Thanks(0)   Quote jheffron Quote  Post ReplyReply Direct Link To This Post Posted: Jul 21 2020 at 5:52pm
I wish they would make the language in these easier for us lay people to read and understand. We are the ones being asked to participate in trials. 
Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 13317
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Jul 21 2020 at 10:16pm
If you are interested in clinical trials, many cancer centers will have a clinical trial coordinator.  That person could possibly answer your questions about the clinical trials.  In addition, if you go out to the clinical trial website, there is a study coordinator/contact person listed.   You could contact that person directly with questions about that specific clinical trial.  I agree these studies are written in scientific language and sometimes difficult to understand, but a good doctor should be able to decipher the information for you.  
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.